Jaguar Animal Health stock analysis
Jaguar Animal Health (1JA2) Stock Price & Analysis
1JA2 Stock Chart & Stats
- Day’s Range
- EUR 94,185.00 - EUR 99,225.00
- 52-Week Range
- EUR 94,185.00 - EUR 99,225.00
- Previous Close
- EUR 99,225.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 836.99K
- Enterprise Value
- EUR 12.45M
- Total Cash (Recent Filing)
- EUR 6.59M
- Total Debt (Recent Filing)
- EUR 16.65M
- Price to Earnings (P/E)
- 0.0
- Beta
- -0.07
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Niche Animal-health Portfolio
Jaguar operates in a specialized animal-health segment with prescription and non-prescription gastrointestinal products addressing defined veterinary needs. This focused portfolio can support differentiated market positioning and provides multiple product avenues for expanding commercial adoption over the next several quarters.
High Gross Margin And Revenue Scale
The company has expanded revenue substantially from $4.3 million in 2021 to $27.8 million TTM and retains an approximately 82% gross margin. That gross-profit profile provides a potentially strong base for operating leverage if revenue stabilizes and expenses become better aligned with scale.
Material Debt Reduction
Reducing debt by more than half improves Jaguar's balance-sheet position and lowers the amount of obligations that must be serviced from operating resources. Although capitalization remains stretched, this deleveraging can improve financial flexibility and reduce pressure on future cash allocation.
Bears Say
Persistent Operating Losses And Cash Burn
Jaguar is not yet converting its commercial operations into dependable cash generation: operating and free cash flow both turned negative in the latest TTM period, while EBIT and net margins remain deeply below zero. Continued losses could require external financing and limit investment capacity.
Thin Capitalization And High Leverage
Despite lower absolute debt, the company's equity cushion remains small relative to its obligations, with debt still about 3.4 times TTM equity. This leaves limited protection if losses continue, increases sensitivity to operating setbacks, and constrains the resources available for sustained growth.
Ongoing Shareholder Dilution
The preferred-stock conversion materially increased the common share base, while the approved proposals also permit additional common-stock issuance linked to preferred stock and debt. Repeated equity expansion can dilute existing holders and make future capital raising more burdensome.
1JA2 FAQ
What was Jaguar Animal Health’s price range in the past 12 months?
What is Jaguar Animal Health’s market cap?
When is Jaguar Animal Health’s upcoming earnings report date?
How were Jaguar Animal Health’s earnings last quarter?
Is Jaguar Animal Health overvalued?
Does Jaguar Animal Health pay dividends?
What is Jaguar Animal Health’s EPS estimate?
How many shares outstanding does Jaguar Animal Health have?
What happened to Jaguar Animal Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Jaguar Animal Health?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Jaguar Animal Health
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lisa A. Conte
- Employees
- 47
- Website
- jaguar.health
- Address
- 200 Pine Street, San Francisco, CA, 94104, US
Jaguar Animal Health (1JA2) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 10 | 3 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 0 | 10 | 0 |
